UK-based Essential Pharma has announced the completion of a 900 million euros ($945 million) financing. The company was ...

Daiichi Sankyo invests $150 million to establish a new antibody-drug conjugate manufacturing facility in Shanghai by 2030, ...

Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...

Utah, USA-based privately-held biotech Halia Therapeutics has announced promising top-line data resulting in the advancement ...

Neuraxpharm Group, a privately-held specialty pharma focused on central nervous system (CNS) disorders, and Greek drugmaker ...

Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...

Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

Minoryx Therapeutics plans to submit European approval for leriglitazone after Phase II NEXUS trial shows 35% disease arrest ...